ライフサイエンスコーパス: onchocerciasis

1 ae in blood (lymphatic filariasis) and skin (onchocerciasis).

2 (p<0.05) following successful treatment for onchocerciasis.

3 88-2001), only 19.6% of cases were caused by onchocerciasis.

4 sms contribute to the pathogenesis of ocular onchocerciasis.

5 iod; 1283 (5.2%) of these deaths were due to onchocerciasis.

6 red during this period; 29.7% were caused by onchocerciasis.

7 tory reactions after ivermectin treatment of onchocerciasis.

8 to play a role in the development of ocular onchocerciasis.

9 le for antibody in the development of ocular onchocerciasis.

10 bove 8 mg, which is the recommended dose for onchocerciasis.

11 Africans who could have been coinfected with onchocerciasis.

12 at promise as a simple tool for diagnosis of onchocerciasis.

13 omes many difficulties in identifying active onchocerciasis.

14 achieve elimination of transmission (EoT) of onchocerciasis.

15 he successful elimination of S. neavei-borne onchocerciasis.

16 ents and skin snips were negative for active onchocerciasis.

17 for Simulium damnosum sensu lato-transmitted onchocerciasis.

18 d the participants of two TaNT campaigns for onchocerciasis.

19 during mass drug administration to eliminate onchocerciasis.

20 Here, we demonstrate NETs formation in human onchocerciasis.

21 rategy in some foci to control and eliminate onchocerciasis.

22 nt regimens against lymphatic filariasis and onchocerciasis.

23 es with a new program that aims to eliminate onchocerciasis.

24 been the drug of choice for the treatment of onchocerciasis.

25 Onchocerca volvulus, the causative agent of onchocerciasis.

26 mosum, which is an important vector of human onchocerciasis.

27 ilariasis, and skin disease and blindness in onchocerciasis.

28 (2,286 to 2,040), cataract (1,846 to 1,690), onchocerciasis (5,577 to 2,871), trachoma (506 to 159),

29 lein-1 ELISA detected antibodies in 34 of 41 onchocerciasis (83%), 38 of 88 leishmaniasis (43%), 18 o

30 The control of river blindness (onchocerciasis), a human disease transmitted by black fl

31 ts to eliminate Simulium neavei- transmitted onchocerciasis, a macroparasitic disease that causes riv

32 Human onchocerciasis, a parasitic disease found in 28 African

33 ion, 14 patients treated with ivermectin for onchocerciasis acquired >10 years ago during temporary r

34 Onchocerciasis, also known as "river blindness", is a ne

35 available and emerging diagnostic tests for onchocerciasis and considers how they might be best empl

36 review the development of models concerning onchocerciasis and discuss the various approaches that h

37 Onchocerciasis and loiasis are coendemic in forest areas

38 A total of 1053 participants from the (onchocerciasis and loiasis coendemic) East Region in Cam

39 We assessed the geographical overlap of onchocerciasis and loiasis prevalence and estimated the

40 ivermectin administration campaigns against onchocerciasis and lymphatic filariasis being conducted

41 drug administration programs for control of onchocerciasis and lymphatic filariasis in Africa.

42 Onchocerciasis and lymphatic filariasis in particular ar

43 Elimination of onchocerciasis and lymphatic filariasis is targeted for

44 crofilaricides to support the elimination of onchocerciasis and lymphatic filariasis.

45 ed helminths and schistosomiasis, as well as onchocerciasis and lymphatic filariasis.

46 than existing anti-Wolbachia drugs that cure onchocerciasis and lymphatic filariasis.

47 matory responses seen following treatment of onchocerciasis and suggest new targets for modulating th

48 n Ov16 with serum samples from patients with onchocerciasis and with various types of control serum s

49 ontribute to the eye defects associated with onchocerciasis and, because there is no counterpart in m

50 The search terms used were "onchocerciasis" AND "ivermectin" AND "mass drug administ

51 in Bakoye and Faleme is consistent with EOT (onchocerciasis) and EPHP (LF) since stopping treatment i

52 We report Ov16 (onchocerciasis) and Wb123 (LF) seroprevalence after 24-2

53 a from parasitic (leishmaniasis, Chagas, and onchocerciasis), and infectious diseases (leprosy and So

54 Serological assessments for human onchocerciasis are based on IgG4 reactivity against the

55 Efforts to control and eliminate onchocerciasis are impeded by a lack of effective treatm

56 More than 99% of cases of onchocerciasis are in sub-Saharan Africa.

57 Lymphatic filariasis and onchocerciasis are neglected tropical diseases (NTDs) ta

58 d, and needed now, in the fight to eliminate onchocerciasis are new tools, such as preventive and the

59 Lymphatic filariasis and onchocerciasis are parasitic helminth diseases that cons

60 Lymphatic filariasis and onchocerciasis are parasitic helminth diseases, which ca

61 Lymphatic filariasis (LF) and onchocerciasis are priority neglected tropical diseases

62 dies of the incidence of blindness caused by onchocerciasis are scarce.

63 diseases, including lymphatic filariasis and onchocerciasis, are considered among the most devastatin

64 utility of molecular xenomonitoring (MX) for onchocerciasis as elimination efforts expand into Africa

65 revalence estimation of strongyloidiasis and onchocerciasis as two relevant examples.

66 rs of biannual MDA (80% coverage) eliminated onchocerciasis-associated epilepsy (OAE) and protected u

67 nlock new possibilities in the fight against onchocerciasis-associated epilepsy (OAE)?

68 r filaricidal agents and/or vaccines against onchocerciasis based on immunological and rational hypot

69 s mortality has been noted among people with onchocerciasis, but it is not clear whether this effect

70 he cornerstone of efforts to eliminate human onchocerciasis by 2020 or 2025.

71 d effort could achieve global elimination of onchocerciasis by 2025.

72 urrently recommends assessing elimination of onchocerciasis by testing whether Ov16 antibody prevalen

73 Our model predicts that onchocerciasis can be eliminated using TaNT in L loa co-

74 the absence of a gold standard, whereas the onchocerciasis case focuses on the identification of vil

75 Lymphatic filariasis and onchocerciasis cases responded well to conventional ther

76 ssociated adverse reactions in patients with onchocerciasis, changes in plasma tryptase levels and sk

77 Human onchocerciasis - commonly known as river blindness - is

78 onated by CHVs' to the African Programme for Onchocerciasis Control alone would be valued between US$

79 doxycycline on a "test and treat" basis for onchocerciasis control and confirm doxycycline as a pote

80 of ivermectin, the predominant strategy for onchocerciasis control and elimination, may not lead to

81 During the past three decades, onchocerciasis control has been successful in reducing b

82 The success of onchocerciasis control has been the result of secure fin

83 t African villages with varying histories of onchocerciasis control measures.

84 rveillance and for evaluating the success of onchocerciasis control measures.

85 Recently, there has been a shift in onchocerciasis control policy, changing from prevention

86 and host mortality with data obtained by the Onchocerciasis Control Programme in West Africa from 231

87 The Onchocerciasis Control Programme in West Africa implemen

88 amined, by use of data collected, during the Onchocerciasis Control Programme in western Africa (OCP)

89 parameter values estimated from the Mexican onchocerciasis control programme.

90 rms responsible for lymphatic filariasis and onchocerciasis, devastating human illnesses.

91 The specificity of skin snips for onchocerciasis diagnoses is considered to be almost 100%

92 implications for a noninvasive host-specific onchocerciasis diagnostic but provides a basis for the m

93 This has important implications for onchocerciasis diagnostic testing in Loa-endemic areas.

94 ed drugs, providing starting points for anti-onchocerciasis drug development.

95 arial infections, yet its neglect undermines onchocerciasis elimination and limits progress toward gl

96 We investigated whether onchocerciasis elimination can be achieved using TaNT an

97 orporated into transmission models to inform onchocerciasis elimination efforts in Africa and residua

98 Loiasis coinfection is a major concern for onchocerciasis elimination in Africa.

99 t for onchocerciasis is needed to accelerate onchocerciasis elimination in Africa.

100 trategy can be scaled up and sustained until onchocerciasis elimination is achieved.

101 be best employed during different stages of onchocerciasis elimination programs.

102 Loa loa microfilariae in the blood preclude onchocerciasis elimination through community-directed tr

103 Onchocerciasis elimination through mass drug administrat

104 Ivermectin-based onchocerciasis elimination, reported in 2009-2012, for B

105 DA) with ivermectin is the main strategy for onchocerciasis elimination.

106 significantly accelerate the achievement of onchocerciasis elimination.

107 from 238 distinct foci in 19 (70%) of the 27 onchocerciasis-endemic countries in sub-Saharan Africa.

108 posttreatment sera from patients treated for onchocerciasis enhanced eosinophil survival; both GM-CSF

109 ter 24-25 years of treatment to determine if onchocerciasis EOT and LF elimination as a public health

110 filariasis) or elimination of transmission (onchocerciasis) for 5 of the most prevalent neglected tr

111 development of an effective vaccine against onchocerciasis has been the focus of a research program

112 Skin snip evaluation for onchocerciasis has insufficient sensitivity when skin mi

113 vaccine candidates and drug targets against onchocerciasis has so far been confronted with several l

114 um damnosum s.l., the vector of West African onchocerciasis, has been the target of a major insect co

115 Although lymphatic filariasis and onchocerciasis have been targeted for global elimination

116 ral malaria, Taenia solium cysticercosis and onchocerciasis - have an established association with ep

117 oinfected people still require treatment for onchocerciasis in 2025 while being at risk of SAEs, just

118 lds in various age groups for elimination of onchocerciasis in a variety of endemic settings and for

119 comes a major obstacle to the elimination of onchocerciasis in areas coendemic for Loa loa.

120 aching programmatic goals for elimination of onchocerciasis in areas that are co-endemic for loiasis.

121 eveloped that include doxycycline to control onchocerciasis in areas where infections persist despite

122 ectin treatment for lymphatic filariasis and onchocerciasis in areas where L. loa infection is endemi

123 als living in an area of hyperendemicity for onchocerciasis in Cameroon were examined.

124 e and under development for the treatment of onchocerciasis in humans - is a leading therapeutic cand

125 To eliminate onchocerciasis in those areas, a test-and-not-treat (TaN

126 s was determined in a murine model of ocular onchocerciasis in which Ags from the parasitic worm Onch

127 tential impact of this intervention on human onchocerciasis infection.

128 ailable for five NTDs (lymphatic filariasis, onchocerciasis, intestinal helminthiasis, schistosomiasi

129 Human onchocerciasis is a serious neglected tropical disease c

130 mectin MDA is not recommended in areas where onchocerciasis is hypo-endemic and L loa is co-endemic.

131 Improved treatment for onchocerciasis is needed to accelerate onchocerciasis el

132 The SD Bioline Onchocerciasis/LF Ig[immunoglobulin]G4 biplex rapid diag

133 nitoring onchocerciasis prevalence by SST in onchocerciasis-loiasis coendemic areas.

134 velopment of chemotherapeutic agents against onchocerciasis, lymphatic filariasis, and heartworm.

135 drug administration drives employed against onchocerciasis, lymphatic filariasis, and several other

136 patients with loiasis, lymphatic filariasis, onchocerciasis, mansonellosis, or other helminthiases an

137 the time to elimination, defined as bringing onchocerciasis mf prevalence below 1.4%.

138 el ONCHOSIM to predict the impact of TaNT on onchocerciasis microfilarial (mf) prevalence.

139 r regulatory submission for the treatment of onchocerciasis, might serve as an alternative to the wid

140 We used 2 onchocerciasis models (EPIONCHO-IBM and ONCHOSIM) to pre

141 l assimilation technique is able to discover onchocerciasis models that reflect local transmission co

142 LF (Brugia malayi, Wuchereria bancrofti) or onchocerciasis (Onchocerca volvulus) is doxycycline.

143 ty treatment strategy for the elimination of onchocerciasis or lymphatic filariasis has been delayed

144 caused by Onchocerca volvulus, resulting in Onchocerciasis or river blindness, or Wuchereria bancrof

145 Onchocerciasis, or river blindness, is a neglected tropi

146 Onchocerciasis, or river blindness, is a neglected tropi

147 h as Onchocerca volvulus, the cause of human onchocerciasis, or river blindness.

148 We assessed the immunoreactivity of onchocerciasis patient sera (n = 152) from the Americas,

149 ive in clearing microfilariae in the skin of onchocerciasis patients with persistent microfilaridermi

150 ain reaction would be useful when monitoring onchocerciasis prevalence by SST in onchocerciasis-loias

151 , we overlaid precontrol maps of loiasis and onchocerciasis prevalence to calculate precontrol preval

152 Attempts to eliminate onchocerciasis, primarily through the mass drug administ

153 Strengthening onchocerciasis programmes, implementing alternative stra

154 ade strongly determines how rapidly national onchocerciasis programs can scale down MDA programs.

155 be considered a host-specific biomarker for onchocerciasis progression.

156 The diagnostic gold standard for onchocerciasis relies on identification and enumeration

157 Nematodes causing lymphatic filariasis and onchocerciasis rely on their bacterial endosymbiont, Wol

158 the rate of blindness from causes other than onchocerciasis remained approximately constant during fo

159 will support future basic and translational onchocerciasis research, with particular relevance for o

160 dentify potential vaccine candidates against onchocerciasis resulted in the cloning of recombinant pr

161 nematodes that cause lymphatic filariasis or onchocerciasis, resulting in blocked worm development an

162 has proposed elimination of transmission of onchocerciasis (river blindness) by 2030.

163 ematodes, including lymphatic filariasis and onchocerciasis (river blindness) has transformed our app

164 gue) and CCR1 using a murine model of ocular onchocerciasis (river blindness) in which neutrophils an

165 Onchocerciasis (river blindness) is a major public healt

166 bundant in the filarial nematodes that cause onchocerciasis (river blindness), including the larvae (

167 us as a natural model or 'analogue' of human onchocerciasis (river blindness), which is caused by Onc

168 ng cause of elephantiasis and hydrocele, and onchocerciasis (river blindness).

169 ol of 5 NTDs-lymphatic filariasis, trachoma, onchocerciasis, schistosomiasis, and soil-transmitted he

170 nse sleeping sickness, lymphatic filariasis, onchocerciasis, schistosomiasis, soil-transmitted helmin

171 ion of drugs to target lymphatic filariasis, onchocerciasis, schistosomiasis, soil-transmitted helmin

172 , schistosomiasis, lymphatic filariasis, and onchocerciasis, suggests that many of them could be cont

173 Since chemotherapy is widely used to treat onchocerciasis, the utility of PCR in assessing response

174 d elimination goals, for others-particularly onchocerciasis-there is a growing consensus that novel t

175 ed methods are needed for field diagnosis of onchocerciasis, to support efforts aimed at elimination

176 In persons with onchocerciasis, topical application of the anthelminthic

177 For schistosomiasis, onchocerciasis, trachoma, and visceral leishmaniasis, a

178 nths, schistosomiasis, lymphatic filariasis, onchocerciasis, trachoma, visceral leishmaniasis, and hu

179 Togo aims to eliminate onchocerciasis transmission (EOT) by 2030.

180 ganization (WHO) has proposed elimination of onchocerciasis transmission (EOT) in a third of endemic

181 An onchocerciasis transmission framework (EpiOncho) was cou

182 are important determinants of elimination of onchocerciasis transmission in sub-Saharan Africa.

183 ntify factors associated with elimination of onchocerciasis transmission in sub-Saharan Africa.

184 e utility of CTSs using our individual-based onchocerciasis transmission model (EPIONCHO-IBM) that pr

185 demiological or entomological assessments of onchocerciasis transmission status in sub-Saharan Africa

186 Due to spatial heterogeneity in onchocerciasis transmission, the duration of ivermectin

187 y if countries are to achieve elimination of onchocerciasis transmission.

188 EPIONCHO-IBM reproduces Togo's onchocerciasis trends throughout five decades of interve

189 es-for example, for eye health (trachoma and onchocerciasis), ulcer care (leprosy), or renal support

190 summarizes the progress made to advance the onchocerciasis vaccine from the research laboratory into

191 d helminths, lymphatic filariasis, trachoma, onchocerciasis, visceral leishmaniasis, and gambiense sl

192 In comparison, trachoma, onchocerciasis, vitamin A deficiency, and refraction and

193 without a history of control measures where onchocerciasis was endemic, microfilariae (MF) prevalenc

194 The number of people infected with onchocerciasis was predicted to decline from almost 19 m

195 Using a mouse model of ocular onchocerciasis, we recently demonstrated that it is thes

196 plains locale-specific infection patterns in onchocerciasis (whereas acquired protective immunity has

197 d to analyse the population biology of human onchocerciasis will be discussed.

198 dministration (MDA) required for eliminating onchocerciasis will vary within endemic areas and the oc

199 Treatment of onchocerciasis with diethylcarbamazine (DEC) or ivermect

200 l serum samples from 10 patients treated for onchocerciasis with diethylcarbamazine.

201 Although suppressive therapy for onchocerciasis with intermittent ivermectin prevents the

202 The coendemicity of onchocerciasis with other filariae warrants a better dia